NRCAM and thyroid gland carcinoma: The protein complex also contains α4β1 integrins, which most likely bind to the third Fn-like domain of NrCAM since antibodies against this domain suppress the MAPK and Akt signaling pathways in thyroid cancer FTC133 cells [88].